AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer von Cross, Darren A E, Ashton, Susan E, Ghiorghiu, Serban, Eberlein, Cath, Nebhan, Caroline A, Spitzler, Paula J, Orme, Jonathon P, Finlay, M Raymond V, Ward, Richard A, Mellor, Martine J, Hughes, Gareth, Rahi, Amar, Jacobs, Vivien N, Red Brewer, Monica, Ichihara, Eiki, Sun, Jing, Jin, Hailing, Ballard, Peter, Al-Kadhimi, Katherine, Rowlinson, Rachel, Klinowska, Teresa, Richmond, Graham H P, Cantarini, Mireille, Kim, Dong-Wan, Ranson, Malcolm R, Pao, William

Volltext

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain von Red Brewer, Monica, Choi, Sung Hee, Alvarado, Diego, Moravcevic, Katarina, Pozzi, Ambra, Lemmon, Mark A., Carpenter, Graham

Volltext

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer von Red Brewer, Monica, Yun, Cai-Hong, Lai, Darson, Lemmon, Mark A, Eck, Michael J, Pao, William

Volltext

HER2 missense mutations have distinct effects on oncogenic signaling and migration von Zabransky, Daniel J, Yankaskas, Christopher L, Cochran, Rory L, Wong, Hong Yuen, Croessmann, Sarah, Chu, David, Kavuri, Shyam M, Brewer, Monica Red, Rosen, D Marc, Dalton, W Brian, Cimino-Mathews, Ashley, Cravero, Karen, Button, Berry, Kyker-Snowman, Kelly, Cidado, Justin, Erlanger, Bracha, Parsons, Heather A, Manto, Kristen M, Bose, Ron, Lauring, Josh, Arteaga, Carlos L, Konstantopoulos, Konstantinos, Park, Ben Ho

Volltext

JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors von Gao, Sizhi P, Chang, Qing, Mao, Ninghui, Daly, Laura A, Vogel, Robert, Chan, Tyler, Liu, Shu Hui, Bournazou, Eirini, Schori, Erez, Zhang, Haiying, Brewer, Monica Red, Pao, William, Morris, Luc, Ladanyi, Marc, Arcila, Maria, Manova-Todorova, Katia, de Stanchina, Elisa, Norton, Larry, Levine, Ross L, Altan-Bonnet, Gregoire, Solit, David, Zinda, Michael, Huszar, Dennis, Lyden, David, Bromberg, Jacqueline F

Volltext

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity von Hanker, Ariella B., Brown, Benjamin P., Meiler, Jens, Marín, Arnaldo, Jayanthan, Harikrishna S., Ye, Dan, Lin, Chang-Ching, Akamatsu, Hiroaki, Lee, Kyung-Min, Chatterjee, Sumanta, Sudhan, Dhivya R., Servetto, Alberto, Brewer, Monica Red, Koch, James P., Sheehan, Jonathan H., He, Jie, Lalani, Alshad S., Arteaga, Carlos L.

Volltext

Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer von Lovly, Christine M, McDonald, Nerina T, Chen, Heidi, Ortiz-Cuaran, Sandra, Heukamp, Lukas C, Yan, Yingjun, Florin, Alexandra, Ozretić, Luka, Lim, Diana, Wang, Lu, Chen, Zhao, Chen, Xi, Lu, Pengcheng, Paik, Paul K, Shen, Ronglai, Jin, Hailing, Buettner, Reinhard, Ansén, Sascha, Perner, Sven, Brockmann, Michael, Bos, Marc, Wolf, Jürgen, Gardizi, Masyar, Wright, Gavin M, Solomon, Benjamin, Russell, Prudence A, Rogers, Toni-Maree, Suehara, Yoshiyuki, Red-Brewer, Monica, Tieu, Rudy, de Stanchina, Elisa, Wang, Qingguo, Zhao, Zhongming, Johnson, David H, Horn, Leora, Wong, Kwok-Kin, Thomas, Roman K, Ladanyi, Marc, Pao, William

Volltext

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers von Sudhan, Dhivya R., Guerrero-Zotano, Angel, Won, Helen, González Ericsson, Paula, Servetto, Alberto, Huerta-Rosario, Mariela, Ye, Dan, Lee, Kyung-min, Formisano, Luigi, Guo, Yan, Liu, Qi, Kinch, Lisa N., Red Brewer, Monica, Dugger, Teresa, Koch, James, Wick, Michael J., Cutler, Richard E., Lalani, Alshad S., Bryce, Richard, Auerbach, Alan, Hanker, Ariella B., Arteaga, Carlos L.

Volltext

EpCAM: Another Surface-to-Nucleus Missile von Carpenter, Graham, Red Brewer, Monica

Volltext

Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting von Du, Zhenfang, Brown, Benjamin P., Kim, Soyeon, Ferguson, Donna, Pavlick, Dean C., Jayakumaran, Gowtham, Benayed, Ryma, Gallant, Jean-Nicolas, Zhang, Yun-Kai, Yan, Yingjun, Red-Brewer, Monica, Ali, Siraj M., Schrock, Alexa B., Zehir, Ahmet, Ladanyi, Marc, Smith, Adam W., Meiler, Jens, Lovly, Christine M.

Volltext

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib von Gallant, Jean-Nicolas, Sheehan, Jonathan H, Shaver, Timothy M, Bailey, Mark, Lipson, Doron, Chandramohan, Raghu, Red Brewer, Monica, York, Sally J, Kris, Mark G, Pietenpol, Jennifer A, Ladanyi, Marc, Miller, Vincent A, Ali, Siraj M, Meiler, Jens, Lovly, Christine M

Volltext

Functional Effects of Glycosylation at Asn-579 of the Epidermal Growth Factor Receptor von Whitson, Kristin B, Whitson, Stefanie R, Red-Brewer, Monica L, McCoy, Austin J, Vitali, Angela A, Walker, Francesca, Johns, Terrance G, Beth, Albert H, Staros, James V

Volltext

Maximizing the benefits of off-target kinase inhibitor activity von Red Brewer, Monica, Pao, William

Volltext

Abstract P4-01-02: A spectrum of secondary mutations in HER2 augment breast cancer cell growth and reduce neratinib sensitivity in HER2 -mutant breast cancer von Marin, Arnaldo Andres, Mamun, Abdullah Al, Akamatsu, Hiroaki, Ye, Dan, Sudhan, Dhivya, Brown, Benjamin, Brewer, Monica Red, Eli, Lisa, Meiler, Jens, Arteaga, Carlos L, Hanker, Ariella B

Volltext

Abstract 867: EGFR kinase domain duplication (EGFR-KDD) is activated by asymmetric intra-molecular dimerization von Du, Zhenfang, Gallant, Jean-Nicolas, Red-Brewer, Monica, Brown, Benjamin, Sheehan, Jonathan, Meiler, Jens, Lovly, Christine M.

Volltext

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression von Schwarz, Luis J, Hutchinson, Katherine E, Rexer, Brent N, Estrada, Mónica Valeria, Gonzalez Ericsson, Paula I, Sanders, Melinda E, Dugger, Teresa C, Formisano, Luigi, Guerrero-Zotano, Angel, Red-Brewer, Monica, Young, Christian D, Lantto, Johan, Pedersen, Mikkel W, Kragh, Michael, Horak, Ivan D, Arteaga, Carlos L

Volltext

Abstract GS6-04: Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity von Hanker, Ariella B., Jayanthan, Harikrishna Sekar, Ye, Dan, Lin, Chang-Ching, Akamatsu, Hiroaki, Sheehan, Jonathan H., Koch, James P., Sudhan, Dhivya R., Brewer, Monica Red, Servetto, Alberto, He, Jie, Miller, Vincent A., Lalani, Alshad S., Meiler, Jens, Arteaga, Carlos L.

Volltext

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA super(H1047R) in HER2/ER-positive breast cancer von Cheng, Feixiong, Zhao, Junfei, Hanker, Ariella B, Brewer, Monica Red, Arteaga, Carlos L, Zhao, Zhongming

Volltext

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA.sup.H1047R in HER2/ER-positive breast cancer von Cheng, Feixiong, Zhao, Junfei, Hanker, Ariella B, Brewer, Monica Red, Arteaga, Carlos L, Zhao, Zhongming

Volltext

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA ^sup H1047R^ in HER2/ER-positive breast cancer von Cheng, Feixiong, Zhao, Junfei, Hanker, Ariella B, Brewer, Monica Red, Arteaga, Carlos L, Zhao, Zhongming

Volltext